En español


124th Meeting of the National Advisory Council on Drug Abuse

Neuroscience Center - Conference Rooms C & D
6001 Executive Boulevard, Bethesda, MD.

September 8, 2016

Closed Session

This meeting is closed to the public in accordance with the provisions set forth in section 552b{c} and 552b{c}(6), Title 5, U.S. Code and section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

9:00 a.m.

Call to Order
Nora Volkow, M.D. Director, NIDA

Review of Policy and Procedures
Susan Weiss, Ph.D.,
Executive Secretary,
National Advisory Council on Drug Abuse,
Director, Division of Extramural Research, NIDA

9:15 a.m.

Council Review of Grant Applications
Nora Volkow, M.D., Director, NIDA

Division of Therapeutics and Medical Consequences (DTMC)
Phil Skolnick, Ph.D., D.Sc., Director

Division of Neuroscience and Behavior (DNB)
Roger Little, Ph.D., D.Sc. (hon.), Acting Director

Division of Epidemiology, Services, and Prevention Research (DESPR)
Carlos Blanco, M.D., Ph.D., Director


10:30 a.m. End of Closed Session/Break

Open Session

11:00 a.m. Opening and Welcome New Members
Nora Volkow, M.D. Director, NIDA
11:15 a.m. Director's Report
Nora Volkow, M.D. Director, NIDA
12:15 p.m. Council Discussion
Council Members
12:45 p.m. Lunch Break (Steering Group Meeting)
2:00 p.m.

Lessons from Marijuana Legalization in Colorado
Andrew Freedman,
Director of Marijuana Coordination,
Office of the Governor,
State of Colorado 

2:40 p.m.

Clinical Studies with an Engineered Cocaine Hydrolase (TV 1380) 
Phil Skolnick, Ph.D., D.Sc. (hon.),
Division of Therapeutics and Medical Consequences, NIDA 

3:20 p.m.


3:30 p.m.

The National Pain Strategy and the Federal Research Agenda
Linda Porter, Ph.D.
Federal Research Agenda Director,
Office of Pain Policy, NINDS, NIH 

4:10 p.m. Public Comments
4:25 p.m. Adjourn

This page was last updated August 2016